PD-1 high expression predicts lower local disease control in stage IV M0 nasopharyngeal carcinoma

PD-1 high expression predicts lower local disease control in stage IV M0 nasopharyngeal carcinoma
复制标题

DOI:
10.1186/s12885-019-5689-y
复制
发表时间:
2019-05-28
期刊:
影响因子:
3.8
通讯作者:
Wei, Qichun
Wei, Qichun
中科院分区:
医学2区
文献类型:
--
作者:
Jiang, Feng;Yu, Wei;Wei, Qichun

文献摘要

被引文献

相似文献

背景肿瘤浸润淋巴细胞(TIL)在肿瘤免疫监视和免疫抑制中发挥着关键作用。了解肿瘤浸润 T 细胞亚群密度、位置和 PD-1/PD-L1 表达可能为预测肿瘤治疗反应和临床结果提供见解。本研究旨在探讨CD8、FoxP3、PD-1和PD-L1在原发肿瘤组织中的表达和定位及其对IV期M0局部晚期鼻咽癌(NPC)患者预后的影响。方法对60例IV期M0局部晚期鼻咽癌患者进行根治性放化疗。通过免疫组织化学分析原发灶肿瘤活检中 CD8、FoxP3、PD-1 和 PD-L1 的表达和定位。分析其与当地疾病控制和鼻咽癌生存的关系。结果平均随访时间为43个月(范围为14至61个月)。 CD8(+)、FoxP3(+)、PD-1(+)和PD-L1(+)的高表达分别在60%、86.7%、56.7%和91.7%的患者中观察到。临床病理特征与这些免疫标志物的表达之间没有相关性。研究发现,PD-1 高表达与局部疾病控制较低相关(5 年 LRFS 为 23.2% vs 96.8%,p
BackgroundTumor-infiltrating lymphocytes (TILs) play a critical role in tumor immune surveillance and immune suppression. Understanding tumor infiltrating T cell subset density, location and PD-1/PD-L1 expression might provide insight for the prediction of tumor therapeutic response and clinical outcome. The purpose of this study was to evaluate the expression and localization of CD8, FoxP3, PD-1, and PD-L1 in primary tumor tissues and their effects on prognosis of stage IV M0 locally advanced nasopharyngeal carcinoma (NPC) patients.MethodsSixty NPC patients with stage IV M0 locally advanced disease were treated with definitive chemoradiation. Tumor biopsies from primary lesion were analyzed for the expression and localization of CD8, FoxP3, PD-1, and PD-L1 by immunohistochemistry. Their associations with local disease control and survival of NPC were analyzed.ResultsThe average follow-up time was 43months (range from 14 to 61months). High expression of CD8(+,) FoxP3(+), PD-1(+) and PD-L1(+) was observed in 60, 86.7, 56.7, and 91.7% of patients, respectively. There was no correlation between clinicopathological features and the expression of these immune markers. High PD-1 expression was found to be associated with lower local disease control (5-year LRFS 23.2% vs 96.8%, p